Katti Jessen

3.0k citations

27 papers · 1.6k indexed · 1 hit paper · h-index 12

Co-authors: Christian Rommel Michael Martin Pingda Ren Matthew R. Janes Shunyou Wang Davide Ruggero Andrew C. Hsieh Kevan M. Shokat
Topics: PI3K/AKT/mTOR signaling in cancer (13 papers)Chronic Lymphocytic Leukemia Research (5 papers)Monoclonal and Polyclonal Antibodies Research (5 papers)
Cited by: Molecular Biology Genetics Oncology
Journals: Nature Journal of Biological Chemistry Journal of Clinical Oncology
Partner nations: United States Spain Italy

In The Last Decade

Katti Jessen

27 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The translational landscape of mTOR signalling steers cancer initiation and metastasis

2012 978 citations Andrew C. Hsieh, Yi Liu et al. Nature profile →

Peers

Countries citing papers authored by Katti Jessen

Since Specialization

Citations

This map shows the geographic impact of Katti Jessen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katti Jessen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katti Jessen more than expected).

Fields of papers citing papers by Katti Jessen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katti Jessen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katti Jessen. The network helps show where Katti Jessen may publish in the future.

Co-authorship network of co-authors of Katti Jessen

This figure shows the co-authorship network connecting the top 25 collaborators of Katti Jessen. A scholar is included among the top collaborators of Katti Jessen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katti Jessen. Katti Jessen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models 2021 ·Blood ·Tiziana Vaisitti,Francesca Arruga,Nicoletta Vitale,(unknown),(unknown),Amy Chadburn,Esteban Braggio,Arianna Di Napoli,Andrea Iannello,John N. Allan,Langdon L. Miller,Brian J. Lannutti,Richard R. Furman,Katti Jessen,Silvia Deaglio	65
2	Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS) 2019 ·Blood ·Tiziana Vaisitti,Katti Jessen,Thanh‐Trang Vo,(unknown),Francesca Arruga,Nicoletta Vitale,Esteban Braggio,Arianna Di Napoli,Amy Chadburn,John N. Allan,Richard R. Furman,Langdon L. Miller,(unknown),Silvia Deaglio	9
3	Development of Cirmtuzumab Antibody-Drug Conjugates (ADCs) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) 2018 ·Blood ·(unknown),George F. Widhopf,Thanh‐Trang Vo,Katti Jessen,Laura Z. Rassenti,Thomas J. Kipps	9
4	Abstract 694: TK-216: a novel, first-in-class, small molecule inhibitor of EWS-FLI1 in early clinical development, for the treatment of Ewing Sarcoma 2017 ·Cancer Research ·Saravana P. Selvanathan,(unknown),Garrett T. Graham,Katti Jessen,Brian J. Lannutti,Aykut Üren,Jeffrey A. Toretsky	8
5	MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells 2016 ·Oncotarget ·Zhihong Zeng,Ruiyu Wang,Yi Hua Qiu,Duncan H. Mak,Kevin R. Coombes,Suk Young Yoo,Qi Zhang,Katti Jessen,Yi Liu,Christian Rommel,(unknown),Hagop M. Kantarjian,Steven M. Kornblau,Michael Andreeff,Marina Konopleva	30
6	eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, Is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL) 2015 ·Blood ·Kevin R. Webster,Vikas Goel,(unknown),Gregory S. Parker,Jocelyn Staunton,(unknown),(unknown),Gary G. Chiang,Katti Jessen,Christopher J. Wegerski,Samuel Sperry,Vera Huang,Joan W. Chen,Peggy A. Thompson,James R. Appleman,Stephen E. Webber,Paul A. Sprengeler,Siegfried Reich	20
7	MLN0128, a Second-Generation mTOR Kinase Inhibitor, Disrupts Survival Signaling and Triggers Apoptosis in AML 2014 ·Blood ·Zhihong Zeng,Ruiyu Wang,Yuexi Shi,Yihua Qiu,Duncan H. Mak,Kevin R. Coombes,Suk Young Yoo,Katti Jessen,Yi Liu,Christian Rommel,Hagop M. Kantarjian,Steven M. Kornblau,(unknown),Michael Andreeff,Marina Konopleva	2
8	Selective Inhibition of Phosphoinositide 3-Kinase p110α Preserves Lymphocyte Function* 2012 ·Journal of Biological Chemistry ·Lomon So,Sung Su Yea,Jean Oak,Mengrou Lu,(unknown),(unknown),Matthew R. Janes,Linda Kessler,Jeff Kucharski,Lian‐Sheng Li,Michael Martin,Pingda Ren,Katti Jessen,Yi Liu,Christian Rommel,(unknown)	59
9	The translational landscape of mTOR signalling steers cancer initiation and metastasisbreakdown → 2012 ·Nature ·Andrew C. Hsieh,Yi Liu,(unknown),Nicholas T. Ingolia,Matthew R. Janes,(unknown),(unknown),Craig R. Stumpf,(unknown),Michael Bonham,Shunyou Wang,Pingda Ren,Michael Martin,Katti Jessen,Morris E. Feldman,Jonathan S. Weissman,Kevan M. Shokat,Christian Rommel,Davide Ruggero	978
10	Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia 2012 ·Leukemia ·Matthew R. Janes,(unknown),Sharmila Mallya,(unknown),Jose J. Limon,Lian‐Sheng Li,Katti Jessen,Michael Martin,Pingda Ren,Michelle M. Lilly,Leonard S. Sender,Yi Liu,Christian Rommel,(unknown)	85
11	Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy 2012 ·Clinical Cancer Research ·Celina García-García,Yasir H. Ibrahim,Violeta Serra,María Teresa Calvo,Marta Guzmán,Judit Grueso,Claudia Aura,José Pérez,Katti Jessen,Yi Liu,Christian Rommel,Josep Tabernero,José Baselga,Maurizio Scaltriti	118
12	Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment 2012 ·Blood ·Zhihong Zeng,Yue Shi,Twee Tsao,Yihua Qiu,Steven M. Kornblau,Keith Baggerly,Wenbin Liu,Katti Jessen,Yi Liu,Hagop M. Kantarjian,Christian Rommel,(unknown),Michael Andreeff,Marina Konopleva	97
13	Abstract 3753: Potent anti-tumor activity of mTOR kinase inhibitor in combination with anti-angiogenic agents in preclinical models of renal cell cancer 2012 ·Cancer Research ·Shunyou Wang,(unknown),(unknown),Katti Jessen,Linda Kessler,Jeff Kucharski,Xin Guo,Jocelyn Staunton,(unknown),(unknown),(unknown),Levan Darjania,(unknown),Katrina Chan,(unknown),Pingda Ren,Christian Rommel,Yi Liu	4
14	Abstract 653: Combination of TORC1/2 and MEK kinase inhibitors in colorectal cancer models 2011 ·Cancer Research ·Celina García-García,Violeta Serra,Maurizio Scaltriti,Yasir H. Ibrahim,Marta Guzmán,Katti Jessen,Yi Liu,Christian Rommel,Josep Tabernero,José Baselga	1
15	Abstract A171: A potent and selective PI3K inhibitor, INK1117, targets human cancers harboring oncogenic PIK3CA mutations. 2011 ·Molecular Cancer Therapeutics ·Katti Jessen,Linda Kessler,Jeff Kucharski,Xin Guo,Jocelyn Staunton,Matthew R. Janes,(unknown),(unknown),(unknown),Shunyou Wang,(unknown),(unknown),Levan Darjania,Lian‐Sheng Li,Katrina Chan,(unknown),Pingda Ren,Christian Rommel,Yi Liu	14
16	Abstract 4486: INK128, a novel TORC1/2 inhibitor with potent oral antitumor activity in preclinical models of renal cancer 2011 ·Cancer Research ·Shunyou Wang,Katti Jessen,Linda Kessler,Jeff Kucharski,(unknown),Xin Guo,Jocelyn Staunton,(unknown),(unknown),Levan Darjania,Lian‐Sheng Li,Katrina Chan,(unknown),Pingda Ren,Christian Rommel,Yi Liu	1
17	482 INK128, a potent and selective TORC1/2 inhibitor, demonstrates anti-tumor activity in preclinical models of renal cell carcinoma by a distinct mechanism 2010 ·European Journal of Cancer Supplements ·(unknown),Katti Jessen,(unknown),Linda Kessler,(unknown),Levan Darjania,(unknown),Ping Ren,Patrick Klein,Christian Rommel	1
18	Monoclonal antibody defines CA 19-9 in pancreatic juices and sera. 1985 ·Gut ·Wolff Schmiegel,(unknown),W. Eberl,R. Arndt,Martin Claßen,H. Greten,Katti Jessen,Holger Kalthoff,N. Soehendra,H.‐G. Thiele	48
19	Multiparametric tumor marker (CA 19-9, CEA, AFP, POA) analyses of pancreatic juices and sera in pancreatic diseases. 1985 ·PubMed ·Wolff Schmiegel,W. Eberl,(unknown),Holger Kalthoff,(unknown),Katti Jessen,R Klapdor,N. Soehendra,Manfred Wargenau,Martin Claßen	11
20	Pancreatic Oncofetal Antigen in Pancreatic Juices 1981 ·Scandinavian Journal of Gastroenterology ·Wolff Schmiegel,Wolf‐Meinhard Becker,R. Arndt,(unknown),N. Soehendra,Katti Jessen,Martin Claßen,H.‐G. Thiele	10

About Katti Jessen

Katti Jessen is a scholar working on Oncology, Genetics and Hematology, having authored 27 papers that have together received 1.6k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (13 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). The work is most often cited by research in Molecular Biology (1.3k citations), Genetics (165 citations) and Oncology (389 citations). Katti Jessen has collaborated with scholars based in United States, Spain and Italy. Frequent co-authors include Christian Rommel, Michael Martin, Pingda Ren, Matthew R. Janes, Shunyou Wang, Davide Ruggero, Andrew C. Hsieh, Kevan M. Shokat, Michael Bonham and Jonathan S. Weissman. Their work appears in journals such as Nature, Journal of Biological Chemistry and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact